Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1868 1
1885 1
1887 3
1936 1
1937 1
1947 1
1948 2
1949 2
1950 6
1951 3
1952 6
1953 3
1954 6
1955 5
1956 4
1957 4
1958 4
1959 8
1960 3
1961 5
1962 1
1963 8
1964 15
1965 17
1966 17
1967 33
1968 26
1969 33
1970 30
1971 21
1972 26
1973 17
1974 21
1975 53
1976 75
1977 60
1978 61
1979 75
1980 70
1981 84
1982 75
1983 91
1984 83
1985 129
1986 116
1987 128
1988 134
1989 187
1990 156
1991 217
1992 239
1993 200
1994 217
1995 273
1996 263
1997 262
1998 286
1999 289
2000 241
2001 279
2002 326
2003 292
2004 304
2005 350
2006 385
2007 341
2008 347
2009 363
2010 412
2011 457
2012 549
2013 594
2014 600
2015 636
2016 670
2017 686
2018 755
2019 860
2020 968
2021 1008
2022 1072
2023 1032
2024 426

Text availability

Article attribute

Article type

Publication date

Search Results

16,580 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Wolny-Kucinska
Page 1
Immunogenicity of TNF-Inhibitors.
Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Atiqi S, et al. Front Immunol. 2020 Feb 26;11:312. doi: 10.3389/fimmu.2020.00312. eCollection 2020. Front Immunol. 2020. PMID: 32174918 Free PMC article. Review.
Retrospectively, we recognize this has led to an underestimation of the amount of ADA produced due to drug interference. Drug-tolerant ADA assays also detect ADA in the presence of drug, which has contributed to the currently reported higher incidence of A …
Retrospectively, we recognize this has led to an underestimation of the amount of ADA produced due to drug interference. Drug-toleran …
The Immunogenicity of Biologic Therapies.
Garcês S, Demengeot J. Garcês S, et al. Curr Probl Dermatol. 2018;53:37-48. doi: 10.1159/000478077. Epub 2017 Nov 7. Curr Probl Dermatol. 2018. PMID: 29131036
The detection of ADA is technically challenging and all assays have limitations, namely a limited capacity in detecting ADA in the presence of a drug due to immune complex (IC) formation, which may underestimate the ADA incidence. Refined assays, able to disr …
The detection of ADA is technically challenging and all assays have limitations, namely a limited capacity in detecting ADA in …
Review of Treatment for Adenosine Deaminase Deficiency (ADA) Severe Combined Immunodeficiency (SCID).
Secord E, Hartog NL. Secord E, et al. Ther Clin Risk Manag. 2022 Sep 22;18:939-944. doi: 10.2147/TCRM.S350762. eCollection 2022. Ther Clin Risk Manag. 2022. PMID: 36172599 Free PMC article. Review.
The most complete form of ADA leads to severe combined immune deficiency (SCID). Treatment with enzyme replacement therapy (ERT) was developed in the 1970s and became the treatment for ADA SCID by the 1980s. ...This review covers the history of ADA SCID, the …
The most complete form of ADA leads to severe combined immune deficiency (SCID). Treatment with enzyme replacement therapy (ERT) was …
5. Lifestyle Management: Standards of Medical Care in Diabetes-2019.
American Diabetes Association. American Diabetes Association. Diabetes Care. 2019 Jan;42(Suppl 1):S46-S60. doi: 10.2337/dc19-S005. Diabetes Care. 2019. PMID: 30559231 Review.
The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality …
The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes ADA's current clinical practice recom …
Adenosine deaminase: functional implications and different classes of inhibitors.
Cristalli G, Costanzi S, Lambertucci C, Lupidi G, Vittori S, Volpini R, Camaioni E. Cristalli G, et al. Med Res Rev. 2001 Mar;21(2):105-28. doi: 10.1002/1098-1128(200103)21:2<105::aid-med1002>3.0.co;2-u. Med Res Rev. 2001. PMID: 11223861 Review.
However, despite a number of studies performed to date, the physiological role played by ADA in the different tissues is not clear. Inherited ADA deficiency causes severe combined immunodeficiency disease (ADA-SCID), in which both B-cell and T-cell developmen …
However, despite a number of studies performed to date, the physiological role played by ADA in the different tissues is not clear. I …
Adenosine Deaminase Deficiency.
Hershfield M, Tarrant T. Hershfield M, et al. 2006 Oct 3 [updated 2024 Mar 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2006 Oct 3 [updated 2024 Mar 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301656 Free Books & Documents. Review.
However, ADA-CID is identified by TMS NBS since the ADA substrates Ado and dAdo are increased. ...An individual who inherits two pathogenic ADA variants will have either ADA-SCID or a delayed or late-onset ADA-CID phenotype that correlates with …
However, ADA-CID is identified by TMS NBS since the ADA substrates Ado and dAdo are increased. ...An individual who inherits t …
Adalimumab in psoriatic arthritis.
Salvarani C, Pipitone N, Catanoso M, Chiarolanza I, Boiardi L, Caruso A, Pazzola G, Macchioni P, Di Lernia V, Albertini G. Salvarani C, et al. J Rheumatol Suppl. 2012 Jul;89:77-81. doi: 10.3899/jrheum.120251. J Rheumatol Suppl. 2012. PMID: 22751600 Review.
ADA was generally well tolerated and its safety profile was similar to that reported in studies of ADA in rheumatoid arthritis. Overall, ADA has a favorable risk-benefit profile in PsA. The combination of ADA and cyclosporine seems to be more effective …
ADA was generally well tolerated and its safety profile was similar to that reported in studies of ADA in rheumatoid arthritis …
TL-ADA: Transferable Loss-based Active Domain Adaptation.
Han K, Kim Y, Han D, Lee H, Hong S. Han K, et al. Neural Netw. 2023 Apr;161:670-681. doi: 10.1016/j.neunet.2023.02.004. Epub 2023 Feb 14. Neural Netw. 2023. PMID: 36841038
In this study, we present a novel Transferable Loss-based ADA (TL-ADA) framework. Our approach is inspired by loss-based query selection, which has shown promising results in active learning. ...Experiments on several benchmark datasets demonstrate that our TL-AD …
In this study, we present a novel Transferable Loss-based ADA (TL-ADA) framework. Our approach is inspired by loss-based query …
Therapeutic Perspectives of Adenosine Deaminase Inhibition in Cardiovascular Diseases.
Kutryb-Zajac B, Mierzejewska P, Slominska EM, Smolenski RT. Kutryb-Zajac B, et al. Molecules. 2020 Oct 12;25(20):4652. doi: 10.3390/molecules25204652. Molecules. 2020. PMID: 33053898 Free PMC article. Review.
ADA is active both inside the cell and on the cell surface where it was found to interact with membrane proteins, such as CD26 and adenosine receptors, forming ecto-ADA (eADA). ...Modulation of ADA activity could be an important therapeutic target. This work …
ADA is active both inside the cell and on the cell surface where it was found to interact with membrane proteins, such as CD26 and ad …
Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease.
Lenders M, Brand E. Lenders M, et al. Front Immunol. 2022 Dec 9;13:1024963. doi: 10.3389/fimmu.2022.1024963. eCollection 2022. Front Immunol. 2022. PMID: 36569886 Free PMC article.
Dose escalation results in a heterogeneous, unpredictable ADA response, with more than a quarter of all treatment switchers succeeding in ADA saturation. Longitudinal ADA measurements are required to assess the individual risk of affected patients....
Dose escalation results in a heterogeneous, unpredictable ADA response, with more than a quarter of all treatment switchers succeedin …
16,580 results
You have reached the last available page of results. Please see the User Guide for more information.